

PRODUCT INFORMATION



DBZ

Item No. 14627

CAS Registry No.: 209984-56-5
Formal Name: N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro-benzeneacetamide

Synonyms: Dibenzazepine, YO-01027

MF: C₂₆H₂₃F₂N₃O₃

FW: 463.5


Purity: ≥98%

UV/Vis.: λ_{max}: 232 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

DBZ is supplied as a crystalline solid. A stock solution may be made by dissolving the DBZ in the solvent of choice, which should be purged with an inert gas. DBZ is soluble in the organic solvent DMSO at a concentration of approximately 45 mg/ml.

DBZ is sparingly soluble in aqueous solutions. To enhance aqueous solubility, dilute the organic solvent solution into aqueous buffers or isotonic saline. If performing biological experiments, ensure the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. We do not recommend storing the aqueous solution for more than one day.

Description

γ-Secretase is a multi-subunit aspartyl protease that cleaves amyloid precursor protein (APP) and many other type 1 transmembrane proteins, including Notch, E-cadherin, and ErbB4.¹ The proteolysis of APP by secretases produces beta amyloid (Aβ), a 39- to 42-amino acid peptide which forms the amyloid plaques that are characteristic of Alzheimer's disease.² DBZ is a dipeptidic inhibitor of γ-secretase that potently blocks the cleavage of Notch into its active signaling effector, Notch intracellular domain, in human T cell lymphoma (SupT1) cells (IC₅₀ = 1.7 nM).³ Within 4 hours after a single 100 μM/kg dose, DBZ demonstrates anti-Alzheimer activity in an APP transgenic mouse model characterized by high levels of Aβ40 by reducing Aβ40 levels by 71%.³

References

1. Dovey, H.F., John, V., Anderson, J.P., *et al.* Functional γ-secretase inhibitors reduce β-amyloid peptide levels in brain. *J. Neurochem.* **76**(1), 173-181 (2001).
2. Wolfe, M.S. Therapeutic strategies for Alzheimer's disease. *Nat. Rev. Drug Discov.* **1**(11), 859-866 (2002).
3. Milano, J., McKay, J., Dagenais, C., *et al.* Modulation of notch processing by γ-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. *Toxicol. Sci.* **82**(1), 341-358 (2004).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/19/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM